OND-PR002

OND-PR002 is a specialized, delayed, pulsatile-release oral formulation of **ondansetron**, a selective serotonin 5-HT3 receptor antagonist. Developed under the National Institute on Drug Abuse (NIDA) Medications Development Program, this formulation is engineered to release the active ingredient in the lower gastrointestinal tract rather than the stomach or upper intestine. This modified pharmacokinetic profile is designed to optimize the modulation of serotonergic pathways involved in the brain's reward circuitry, specifically for the treatment of stimulant use disorders. OND-PR002 has been investigated primarily in combination with immediate-release methylphenidate (Ritalin) to address **methamphetamine dependence** and **cocaine dependence**, where 5-HT3 antagonism is hypothesized to reduce drug-induced dopamine release and associated cravings.

Other names

pulsatile-release ondansetrondelayed-release ondansetronondansetron PR